Clinically relevant liver, kidney or bone marrow abnormalities (as defined by specific clinical chemistry values)
Allergies towards Gd-DTPA
Allergies towards constituents of the therapeutic agent
Recruitment to other clinical trials within 6 months prior to or during this study
Pretreatment with complete lymph irradiation, antibody therapy against lymphocyte populations (eg. anti-CD4, Campath-1H), mitoxantrone, cyclophosphamide, cyclosporin A, human antibodies, all immunomodulatory or immunosuppressive agents including recombinant cytokines or other potential experimental MS therapies (6 months prior to study start), glatiramer acetate, azathioprine, IVIg (6 months prior to study start) pregnancy or lactation
Alcohol or drug abuse
Inhibitors of Cytochrom P 450 3A (eg. cyclosporin, macrolide antibiotics, azole antimycotics).
Medical or psychological conditions that could hamper with the patients capacity to understand patient information, to give the informed consent, to adhere to the protocol of the study and to be able to complete the study
Clareo Health | Atorvastatin in Relapsing-Remitting Multiple Sclerosis
